Moleculin Biotech, Inc. 8-K

What Happened

• Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on May 15, 2026 (Item 2.02) to announce its financial results and recent operational highlights for the quarter ended March 31, 2026. The company issued a press release on May 15, 2026 reporting those quarterly results; that press release is attached to the filing as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: May 15, 2026 (Form 8-K, Item 2.02).
• Reporting period: quarter ended March 31, 2026.
• Disclosure vehicle: press release dated May 15, 2026 attached as Exhibit 99.1 to the 8-K.
• The 8-K reports results of operations and financial condition (Item 2.02); Exhibit 104 (iXBRL cover page) is included.

Why It Matters

• This filing is the company’s official disclosure of its latest quarterly earnings and operational updates — core information investors use to assess recent performance and near‑term prospects. Investors should review the attached press release for the specific financial figures (revenue, net income/loss, cash position) and any program or milestone updates that could affect Moleculin’s valuation or near-term catalysts.